Addus HomeCare has now reported, and the extreme put positioning flagged ahead of yesterday's print has delivered its verdict — the stock fell 2.7% on Tuesday to $113.66, extending a 4.7% weekly decline, as the defensive hedges that dominated pre-earnings options flow proved well-placed.
The options story has shifted slightly but not resolved. The put/call ratio eased fractionally to 4.25 from Monday's 52-week high of 4.36, yet it remains more than two standard deviations above its 20-day mean of 0.76. That persistent skew tells you the hedges were not unwound after the print — whoever bought those puts is holding, suggesting the market has not yet cleared the air around the result. The post-earnings day-one move was a relatively modest -1.6%, well within the range of routine reactions for a stock of this size.
Short interest tells a more nuanced story now. Bears added positions aggressively through late July — SI climbed roughly 30% over the past month to reach 7.2% of the free float, the highest level in that period. But the week-on-week move has nearly stalled: SI edged up just 0.4% in the latest reading. The borrow market remains deeply relaxed, with availability at 723% — roughly seven shares available for every one currently borrowed — and cost to borrow running at just 0.60%, up 27% on the week but still at levels that impose no meaningful friction on new shorts. With SI at 7% of float and borrow this loose, the positioning looks considered rather than frantic.
The Street reaction to the earnings release tells a cleaner story. RBC Capital's Ben Hendrix raised his target to $134 from $130 this morning while maintaining Outperform — a constructive post-print response from a firm that has been consistently bullish. That puts the mean analyst target at $134.69, implying roughly 19% upside to Tuesday's close. The lone bear on the panel, Barclays, holds Underweight with a $96 target set in early July, which is now 16% below the current price. Bulls point to M&A optionality across the Personal Care, Hospice, and Home Health segments; bears flag funding reform risk and labor constraints as structural caps on margin. The PE multiple, near 15.9x, has expanded roughly 1.3 points over the past month, reflecting the stock's prior month-long rally even as this week erased some of those gains. Factor scores are broadly neutral — the short score ranks in the 24th percentile, consistent with a modest-but-notable short position, while EPS momentum sits in the 43rd percentile.
Among peers, the week's divergence is worth noting. OPCH gained 5.4% and CHE added 4.3% over the same period that ADUS fell 4.7%. PNTG dropped 8.1% and HCA lost 4.2%, suggesting the weakness is not sector-wide. AHCO suffered a severe -40% week — an outlier that reflects company-specific news rather than sector pressure. ADUS sitting in the middle of this range implies the post-earnings dip is stock-specific rather than a broader home-care selloff.
The next earnings event is slated for November 2. Between now and then, the question is whether the options market normalises back toward its pre-July PCR levels below 0.2, and whether short sellers who built positions ahead of the print choose to cover after a relatively contained reaction or maintain pressure into the next quarter.
See the live data behind this article on ORTEX.
Open ADUS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
